Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study

Elise A Mitri1,2,3, Luke R Fletcher4,5,6, Sara Vogrin1,2

  • 1Department of Infectious Diseases and Immunology, Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, Victoria, Australia.

Insights

Inpatient penicillin direct oral challenge (DOC) is safe and effective for penicillin allergy assessment. This method improved penicillin prescribing and reduced the use of restricted antibiotics in hospitalized patients.

Area of Science:

  • Infectious Diseases
  • Clinical Pharmacology
  • Health Services Research

Background:

  • Penicillin allergy is reported by ~10% of hospitalized patients globally, leading to suboptimal antibiotic use and poorer outcomes.
  • Limited evidence exists on the effectiveness and implementation of inpatient penicillin direct oral challenge (DOC).

Purpose of the Study:

  • To evaluate the effectiveness and implementation of an inpatient penicillin DOC strategy.
  • To assess the impact of DOC on antibiotic prescribing patterns.

Main Methods:

  • A prospective, multicenter, international hybrid effectiveness-implementation study involving 40 hospitals.
  • Adult inpatients with penicillin allergy were assessed using the National Antibiotic Allergy Network (NAAN) App and underwent DOC or assessment only.
  • Audit and feedback were provided to sites, and observational data emulated a target trial.

Main Results:

  • Of 5121 assessed, 1573 underwent DOC, with 95.5% successfully delabeled.
  • DOC participants were more likely to receive penicillin (RR 13.25) and less likely to receive WHO "Watch" or "Reserve" antibiotics (RR 0.73).
  • 77 clinicians adopted the NAAN App within 6 months.

Conclusions:

  • Multidisciplinary adoption of inpatient penicillin DOC is safe and feasible.
  • Penicillin DOC significantly improved penicillin prescribing and reduced the use of restricted antibiotics.
Abstract

Related Concept Videos

Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
181
Allergic Reactions02:06

Allergic Reactions

Overview
33.6K
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
67
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
145